Medicinal Chemistry is a multidisciplinary field integrating chemistry, biology, pharmacology, and pharmacokinetics to design therapeutic chemical compounds. The goal is to discover and optimize drugs for treating diseases by understanding biological targets, designing interacting molecules, and enhancing their properties.
Vipragen is a leading partner in integrated drug discovery, offering expertise in medicinal chemistry to accelerate pharmaceutical research. Their scientists excel in computational chemistry, in vitro and in vivo biology, drug metabolism, and toxicology, delivering successful preclinical and clinical candidates across various therapeutic areas like oncology and autoimmune disorders.
Our knowledge-based approach relies on the wealth of expertise within our team of researchers. This involves leveraging existing biological knowledge, insights from previous studies, and an understanding of the target of interest. By drawing on collective experience and established principles in medicinal chemistry, this approach enables the identification of potential hits based on known mechanisms and interactions.
Concurrently, our in silico/CADD-based approach harnesses the power of computational tools and algorithms. Utilizing advanced software and predictive modeling, we perform virtual screening and molecular docking simulations to evaluate the potential interactions between target proteins and diverse chemical entities. This allows for the identification of hits with a higher probability of exhibiting the desired biological activity.
One of the distinctive strengths of Vipragen's hit identification process is the parallel execution of these dual approaches. Knowledge-based and in silico/CADD methodologies complement each other, providing a comprehensive and well-rounded assessment of potential hits. This parallel execution not only accelerates the overall hit identification timeline but also enhances the probability of identifying novel and promising compounds.
Vipragen employs a dual approach to hit identification, combining knowledge-based and in silico/CADD methodologies for a robust drug discovery process. The knowledge-based approach leverages established principles and biological insights, while the in silico/CADD approach explores vast chemical space to uncover compounds not apparent through traditional methods. This integrated strategy demonstrates Vipragen's commitment to innovation and efficiency in drug discovery, navigating hit identification complexities. Our multidisciplinary team seamlessly collaborates in assessing hits, refining compounds, and delivering high-quality drug candidates during hit-to-lead and lead optimization phases, driving drug discovery forward.
Leveraging extensive scientific expertise, our team optimizes hits and identifies the most promising active compounds for progression to the lead optimization stage. Our capabilities encompass:
Building upon the identified lead compound from the hit-to-lead stage, our scientists focus on optimizing and evaluating the leads through various screening studies until a suitable preclinical candidate is achieved. Our lead optimization capabilities include:
Our Discovery Chemistry services boast an in-house dedicated chemical reaction screening facility, facilitating rapid go/no-go decisions.